ROCKVILLE, Md., Sept. 20, 2007 (PRIME NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF - News) today announced that the FDA has granted marketing clearance for the AutoloGel(tm) System. The indications for use are as follows: Under the supervision of a healthcare professional, the PRP gel produced by the AutoloGel(tm) System is suitable for exuding wounds, such as leg ulcers, pressure ulcers, diabetic ulcers and for the management of mechanically or surgically-debrided wounds.
